Remicade Helped By “Slow Start” To Medicare Part B Demo
This article was originally published in The Pink Sheet Daily
Executive Summary
Johnson & Johnson's rheumatoid arthritis therapy Remicade is feeling virtually no impact from a Medicare demonstration project that provides coverage to competing agents, Group Chairman-Biopharmaceuticals Joe Scodari said during the Bear Stearns health care conference in New York Sept. 13
You may also be interested in...
Enbrel Psoriatic Arthritis Indication Added To Medicare Part B Demo
The Centers for Medicare & Medicaid Services has added coverage of Wyeth/Amgen's Enbrel (etanercept) for psoriatic arthritis to its Part B demonstration project
Enbrel Psoriatic Arthritis Indication Added To Medicare Part B Demo
The Centers for Medicare & Medicaid Services has added coverage of Wyeth/Amgen's Enbrel (etanercept) for psoriatic arthritis to its Part B demonstration project
Medicare Part B Average Sales Prices Will Be Published In December – CMS
2005 payment rates, which will be based on third quarter 2004 data supplied by manufacturers, will not be ready in time to be included in CMS's final Physician Fee Schedule rule, which the agency plans to release Nov. 1. The final rule will also include recommended billing code changes.